Business Context and Reporting Period
Company: Safety Shot, Inc. (Note: Request metadata listed "BONK, INC." but filing identifies "SAFETY SHOT, INC.")
Filing Type: Form 8-K (Current Report)
Date: April 10, 2025
Context: The Company, an emerging growth company incorporated in Delaware, reported the entry into a material definitive agreement involving an amendment to a consulting contract and a new warrant purchase agreement with Core 4 Capital Corp.
Key Financial Metrics and Transaction Details
This filing does not report standard financial performance metrics (revenue, profit, cash flow, margins, or debt). It details specific capital transactions:
- Consulting Agreement Amendment: Extension of term to April 1, 2026.
- Equity Issuance (Consulting): Agreement to issue 2,500,000 additional restricted shares of common stock.
- Warrant Purchase: Sale of 4,000,000 warrants for an aggregate purchase price of $500,000 ($0.125 per warrant).
- Warrant Terms: Exercise price of $0.41 per share; expiration date of April 10, 2030.
Material Changes and Related Party Transactions
Consulting Extension: The original six-month consulting agreement (commencing October 1, 2024) has been extended by one year. The vesting schedule for the new 2,500,000 shares is quarterly, with the first tranche vesting on June 30, 2025.
Related Party Disclosure: The transaction involves a related party. Jordan Schur, the Company's President, owns 15% of the Consultant (Core 4 Capital Corp.). Other shareholders of the Consultant are members of Mr. Schur's immediate family.
Regulatory Status: The securities (warrants and shares) were issued without prior registration, relying on exemptions under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future operational performance.
Risks and Contingencies:
- Dilution Risk: The issuance of 2,500,000 shares and 4,000,000 warrants may result in shareholder dilution.
- Related Party Risk: The transaction involves significant related party interests, which may present conflicts of interest.
- Liquidity: While the Company received $500,000 in cash from the warrant sale, the filing does not provide a broader liquidity assessment.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance to assess dilution impact.
- Confirm the vesting conditions and performance metrics (if any) attached to the 2,500,000 consulting shares.
- Review the full text of the Consulting Agreement Amendment (Exhibit 10.1) and Warrant Purchase Agreement (Exhibit 10.2) for restrictive covenants.
- Assess the financial necessity of the $500,000 warrant sale given the Company's current cash position (not disclosed in this filing).
- Monitor future filings for disclosure of the actual cash received and the timing of share vesting.